放化疗联合贝伐珠单抗靶向治疗晚期卵巢癌 32例

目的 放化疗联合贝伐珠单抗(Bevacizumab)靶向治疗对晚期卵巢癌病人生存时间、毒副反应及细胞免疫功能的影响.方法 选取2012年1月至2014年1月于成都市第五人民医院接受治疗的64例晚期卵巢癌病人作为研究对象,根据治疗方法的不同分为对照组与观察组,各32例,对照组采用全腹放疗联合紫杉醇+卡铂(TC)方案化疗,观察组在对照组治疗的基础上联合Bevacizumab靶向治疗,比较治疗前后两组病人的细胞免疫功能,T细胞亚群(CD3+、CD4+、CD4+/CD8+)及自然杀伤(NK)细胞水平变化;比较治疗后两组病人的临床疗效、生存时间;观察治疗过程中两组病人毒副反应.结果 与治疗前相比,治疗后观察病人的CD3+、CD4+、CD4+/CD8+及NK细胞水平均升高,差异有统计学意义(P<0.05);与治疗后对照组相比,治疗后观察组病人的CD3+、CD4+、CD4+/CD8+及NK细胞水平升高,差异有统计学意义(P<0.05);治疗后,观察组病人的总有效率、1年生存率、3年生存率及生存时间分别为65.63％、81.25％、56.25％、(26.37±4.67)月,均显著高于对照组的21.88％、56.25％、31.25％、(18.62±3.75)月,差异有统计学意义(P<0.05);两组病人毒副反应发生情况比较,差异无统计学意义(P>0.05).结论 采用放化疗联合Bevaci-zumab靶向治疗晚期卵巢癌病人可延长病人生存时间、提高病人细胞免疫功能,同时,不会增加毒副反应.

Targeted treatment of 32 cases of advanced ovarian cancer with radiotherapy and chemotherapy combined with bevacizumab

Objective To investigate the effects of radiotherapy and chemotherapy combined with Bevacizumab targeted therapy onsurvival time, toxicity and side effects and cellular immune function in patients with advanced ovarian cancer.Methods Sixty-four patients with advanced ovarian cancer who were treated in Chengdu Fifth People''s Hospital from January 2012 to January 2014 were selected as the research objects. According to the different treatment methods, patients were assigned into control group and observation group,with 32 cases in each group. The control group received full abdomen radiotherapy combined with paclitaxel+carboplatin (TC) regimenchemotherapy, while the observation group received Bevacizumab targeted therapy on the basis of the control group. The cellular immunefunctions: the changes of T cell subsets (CD3+, CD4+, CD4+/CD8+) and natural killer (NK) cell levels, of the two groups were comparedbefore and after treatment, the clinical efficacy and survival time of the two groups were compared after treatment, and the toxicity andside effects of the two groups were observed during the treatment.Results Compared with before treatment, the levels of CD3+, CD4+,CD4+/CD8+ and NK cells in the patients after treatment were significantly higher, the differences were significant (P< 0.05). Comparedwith the control group after treatment, the levels of CD3+, CD4+, CD4+/CD8+ and NK cells in the observation group increased significantly after treatment, the differences were significant (P<0.05). After treatment, the total effective rate, 1-year survival rate, 3-year survivalrate and average survival time of the patients in the observation group were 65.63%, 81.25%, 56.25% and (26.37±4.67) months, respectively, which were significantly higher than those in the control group 21.88%, 56.25%, 31.25% and (18.62±3.75) months], and the differences were significant (P<0.05). There was no statistically significant difference in the occurrence of toxic and side effects between the two groups (P>0.05).Conclusion Radiotherapy and chemotherapy combined with Bevacizumab targeted therapy can prolong the survival time of patients with advanced ovarian cancer, improve the cellular immune function of patients, without increasing toxic side effects .